SEFA SENOL*, MUZAFFER BAHCIVAN**, AHMET YUKSEL***, MEHMET UGUR ES****
*Department of Cardiovascular Surgery, Elazig Education and Research Hospital, Elazig, Turkey -
**Department of Cardiovascular Surgery, Memorial Diyarbakir Hospital, Diyarbakir, Turkey -
***Department of Cardiovascular Surgery, Bingol State Hospital, Bingol, Turkey -
****Department of Cardiovascular Surgery, Medicalpark Tokat Hospital, Tokat, Turkey
Introduction: The aim of this study was to investigate the effects of Adducin Gly460Trp, and methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C gene polymorphisms that are supposed to play a role in atherothrombotic process in patients with peripheral arterial disease (PAD).
Materials and methods: This prospective study was performed on a total of 270 participants between January 2013 and June 2014. The participants were divided into two groups: Group 1 (PAD group) included 180 patients with PAD (mean age: 55±18 years, 128 males), and Group 2 (control group) included 90 participants (mean age: 53±15 years, 61 males) with normal physical examination and arterial duplex ultrasonography findings for PAD. Groups were compared with each other according to the clinical and demographic characteristics, levels of some biochemical parameters, allele frequencies, and particularly Adducin Gly460Trp, MTHFR C677T and A1298C gene polymorphisms, which were determined by using real time polymerase chain reaction.
Results: The incidences of hypertension, diabetes mellitus, smoking, family history of cardiovascular diseases and fasting glucose levels were significantly higher in PAD group. Both groups were statistically similar according to the levels of total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglyceride, urea and creatinine. Comparison of both groups according to the Adducin Gly460Trp, MTHFR C677T and A1298C gene polymorphisms, and allele frequencies did not yield any statistically significant differences.
Conclusion: We concluded that Adducin Gly460Trp, MTHFR C677T and A1298C gene polymorphisms were not predictive factors for PAD. The investigations on different polymorphisms of Adducin and MTHFR may be beneficial.
Adducin; methylenetetrahydrofolate reductase; gene polymorphism; peripheral arterial disease.